이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma

2026년 6월 29일 업데이트: Aveta Biomics, Inc.

A Multicenter, Randomized, Open-Label Phase 3 Study of APG-157 as Neoadjuvant Therapy or as Induction and Maintenance Therapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

This Phase 3, multicenter, randomized, open-label study evaluates APG-157 in adults with newly diagnosed locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Two independently powered cohorts are enrolled based on treatment pathway. Cohort A evaluates APG-157 administered as neoadjuvant therapy before curative-intent surgery in participants with resectable oral cavity or oropharyngeal cancer who are medically ineligible for perioperative pembrolizumab. Cohort B evaluates APG-157 administered as induction therapy before definitive chemoradiotherapy and as maintenance therapy after chemoradiotherapy in participants with unresectable or medically inoperable disease. Participants are randomized 1:1 within each cohort to receive APG-157-based treatment or standard-of-care therapy. The primary hypothesis is that APG-157 given before definitive surgery followed by (chemo)radiotherapy improves event-free survival (EFS) compared to surgery and adjuvant (chemo)radiotherapy alone (Cohort A), and that APG-157 given as induction therapy prior to definitive chemoradiotherapy (CRT) followed by maintenance APG-157 improves EFS compared to definitive CRT alone (Cohort B).

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

This Phase 3, multicenter, randomized, open-label study evaluates APG-157 in adults with newly diagnosed locally advanced head and neck squamous cell carcinoma (LA-HNSCC). The study consists of two independently powered cohorts designed to evaluate APG-157 in distinct treatment settings. Cohort A enrolls participants with resectable oral cavity or oropharyngeal squamous cell carcinoma who are objectively medically ineligible for perioperative pembrolizumab according to protocol-defined criteria. Participants are randomized 1:1 to receive APG-157 administered orally at 600 mg/day for 6 weeks prior to curative-intent surgical resection followed by protocol-directed adjuvant therapy, or standard-of-care surgery followed by adjuvant therapy alone. Cohort B enrolls participants with unresectable or medically inoperable locally advanced oropharyngeal squamous cell carcinoma. Participants are randomized 1:1 to receive APG-157 induction therapy for 4 weeks before definitive chemoradiotherapy, followed by APG-157 maintenance therapy initiated within 60 days after chemoradiotherapy and continued for up to 1 year, or standard-of-care definitive chemoradiotherapy alone.The primary objective is to determine whether APG-157-based treatment improves event-free survival compared with standard-of-care treatment. Key secondary objectives include overall survival, objective response, pathological response, ctDNA clearance, safety, treatment feasibility, and patient-reported outcomes.

연구 유형

중재적

등록 (추정된)

826

단계

  • 3단계

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria

Cohort A (Resectable Disease)

  1. Adults ≥18 years
  2. Histologically or cytologically confirmed, previously untreated locally advanced head and neck squamous cell carcinoma (LA-HNSCC) of the oral cavity or oropharynx.
  3. Resectable disease appropriate for curative-intent surgery.

  4. Stage III-IVA disease according to AJCC criteria:

    • Oropharynx, p16-positive: Stage III (T4, N0-N3, M0)
    • Oropharynx, p16-negative: Stage III or IVa (T3-T4, N0-N2, M0)
    • Oral cavity: Stage III or IVa (T3-T4, N0-N2, M0)
  5. Objectively medically ineligible for perioperative pembrolizumab according to protocol-defined objective criteria.
  6. HPV/p16 testing available for stratification.
  7. Measurable or evaluable disease.
  8. Life expectancy ≥12 months.
  9. ECOG Performance Status ≤2.
  10. Negative pregnancy test for women of childbearing potential and agreement to use effective contraception.
  11. Ability to comply with study procedures.

Cohort B (Unresectable / Medically Inoperable Disease)

  1. Adults ≥18 years
  2. Histologically or cytologically confirmed, previously untreated LA-HNSCC of the oropharynx. Disease not suitable for curative-intent surgery.

  3. Stage III-IVA disease according to AJCC criteria:

    • p16-positive Stage III (T4, N0-N3, M0) with >10 pack-year smoking history
    • p16-negative Stage III or IVa (T3-T4, N0-N2, M0)
  4. HPV/p16 testing available for stratification.
  5. Presence of evaluable tumor burden.
  6. Eligible to receive definitive chemoradiotherapy.
  7. Life expectancy ≥12 months.
  8. ECOG Performance Status ≤2.
  9. Adequate organ function.
  10. Contraception requirements met.
  11. Ability to comply with study procedures.

Exclusion Criteria

Cohort A Specific:

  • Stage I-II disease
  • Stage IVb or Ivc disease
  • T4b unresectable disease
  • N3 disease where applicable
  • Medically eligible for perioperative pembrolizumab

Cohort B Specific:

  • Stage I-II disease
  • Disease not appropriate for curative-intent CRT
  • Active autoimmune disease requiring systemic therapy
  • Prior solid organ or allogeneic stem cell transplant
  • Ongoing immunosuppression >10 mg/day prednisone equivalent

Common Exclusion Criteria:

  • Primary tumor arising from the nasopharynx, hypopharynx, larynx, paranasal sinus, or unknown primary site.
  • Prior treatment for current head and neck squamous cell carcinoma.
  • Prior malignancy unless protocol exceptions met
  • Distant metastatic disease
  • Live vaccine within 30 days
  • Known hypersensitivity to APG-157 or its components.
  • Unresolved clinically significant toxicity
  • Recent participation in another investigational study
  • Active uncontrolled infection
  • Significant uncontrolled cardiovascular disease
  • Pregnancy or breastfeeding.
  • QTcF >500 msec or congenital long QT syndrome
  • Any condition compromising safety, compliance, or study interpretation

Randomization ratio: 1:1 within each cohort

Stratification Factors:

Cohort A:

  • HPV/p16 status,
  • Planned platinum strategy,
  • PD-L1 CPS category

Cohort B:

  • HPV/p16 status
  • Planned platinum strategy
  • Geographic region.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort A - APG-157
APG-157 600 mg/day (200 mg orally three times daily)for 6 weeks prior to curative-intent surgery followed by protocol-directed adjuvant therapy.
의약품: APG-157
APG-157 is a first-in-class investigational drug product, formulated as 100 mg soft hydrogel pastille to dissolve in the mouth
절차: Surgery
Definitive Surgery
방사능: Radiation/Chemotherapy
Protocol-specified risk-adapted postoperative radiotherapy, with concurrent platinum-based chemotherapy (e.g., cisplatin or carboplatin) administered when indicated based on pathological risk factors
방사능: Radiation/Chemotherapy
Definitive radiotherapy with concurrent protocol-specified platinum-based chemotherapy.
활성 비교기: Cohort A - Control
Standard-of-care surgery and adjuvant therapy; Participants undergo curative-intent surgery followed by protocol-directed adjuvant therapy
절차: Surgery
Definitive Surgery
방사능: Radiation/Chemotherapy
Protocol-specified risk-adapted postoperative radiotherapy, with concurrent platinum-based chemotherapy (e.g., cisplatin or carboplatin) administered when indicated based on pathological risk factors
방사능: Radiation/Chemotherapy
Definitive radiotherapy with concurrent protocol-specified platinum-based chemotherapy.
실험적: Cohort B - APG-157
APG-157 induction therapy and standard-of-care definitive chemoradiotherapy followed by APG-157 maintenance therapy. Participants receive APG-157 600 mg/day for 4 weeks (200 mg orally three times daily) prior to definitive chemoradiotherapy, followed by APG-157 maintenance therapy for up to 1 year
의약품: APG-157
APG-157 is a first-in-class investigational drug product, formulated as 100 mg soft hydrogel pastille to dissolve in the mouth
방사능: Radiation/Chemotherapy
Protocol-specified risk-adapted postoperative radiotherapy, with concurrent platinum-based chemotherapy (e.g., cisplatin or carboplatin) administered when indicated based on pathological risk factors
방사능: Radiation/Chemotherapy
Definitive radiotherapy with concurrent protocol-specified platinum-based chemotherapy.
활성 비교기: Cohort B - Control
Standard-of-Care Chemoradiotherapy. Participants receive definitive upfront chemoradiotherapy
방사능: Radiation/Chemotherapy
Protocol-specified risk-adapted postoperative radiotherapy, with concurrent platinum-based chemotherapy (e.g., cisplatin or carboplatin) administered when indicated based on pathological risk factors
방사능: Radiation/Chemotherapy
Definitive radiotherapy with concurrent protocol-specified platinum-based chemotherapy.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Event-Free Survival (EFS)
기간: From randomization until the first occurrence of a protocol-defined EFS event, death, withdrawal from study follow-up, or study completion, assessed for up to approximately 36 months.

EFS is defined as the time from randomization to the earliest occurrence of a protocol-defined EFS event, including radiographic and/or clinical disease progression that precludes initiation or completion of planned definitive curative-intent therapy; locoregional recurrence, progression, or distant metastasis following definitive treatment, confirmed by imaging, pathology, salvage intervention with viable tumor or other protocol-defined assessments, where applicable, or death from any cause.

EFS will be analyzed by blinded independent central review (BICR) using RECIST v1.1 and protocol-defined pathology criteria, as applicable. The primary analysis will be conducted in the intent-to-Treat ( ITT) population using stratified log-rank testing and Cox proportional hazards models.
From randomization until the first occurrence of a protocol-defined EFS event, death, withdrawal from study follow-up, or study completion, assessed for up to approximately 36 months.

2차 결과 측정

결과 측정
측정값 설명
기간
Overall Survival (OS)
기간: Time from randomization until death from any cause; assessed up to approximately 60 months.
Overall survival is defined as the time from randomization until death from any cause.
Time from randomization until death from any cause; assessed up to approximately 60 months.
Objective Response Rate (ORR)
기간: • Cohort A: Week 6 and pre-surgery assessment • Cohort B: Week 4 and pre-CRT assessment
Proportion of participants achieving confirmed response (CR) or partial response (PR) according to RECIST v1.1 as assessed by BICR.
• Cohort A: Week 6 and pre-surgery assessment • Cohort B: Week 4 and pre-CRT assessment
ctDNA Clearance Rate
기간: Baseline through protocol-defined follow-up assessments up to approximately 36 months.
Change in circulating tumor DNA (ctDNA) levels over time and proportion of participants achieving ctDNA clearance from the baseline assessed using a tumor-informed assay.
Baseline through protocol-defined follow-up assessments up to approximately 36 months.
Clinically Meaningful Pathological Response(Cohort A):
기간: At definitive surgery (approximately 6-9 weeks after randomization).
Proportion of participants achieving ≤50% residual viable tumor in the resected specimen as assessed by BICR.
At definitive surgery (approximately 6-9 weeks after randomization).
Major Pathologic Response (MPR) (Cohort A)
기간: At definitive surgery.
Proportion of participants achieving ≤10% residual viable tumor in the resected specimen as assessed by BICR.
At definitive surgery.
Composite Pathologic Response (Cohort A)
기간: At definitive surgery.

Composite assessment including:

  • Pathologic tumor response category
  • Surgical margin status
  • Extranodal extension status
  • Clinical-to-pathologic downstaging
At definitive surgery.
Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Treatment Discontinuations Due to Adverse Events
기간: From first dose through 30 days after last study treatment.
From first dose through 30 days after last study treatment.
Ability to Initiate Definitive Therapy
기간: Up to 21 days after last dose of APG-157
Proportion of participants able to initiate protocol-defined definitive curative-intent therapy within protocol-specified timing windows (Within 21 days after the last dose of APG-157 prior to definitive surgery (Cohort A) or definitive chemoradiotherapy (Cohort B))
Up to 21 days after last dose of APG-157
Patient-Reported Outcomes
기간: Baseline through approximately 36 months.
EuroQol-5 Dimension, 5-Level (EQ-5D-5L). Change from baseline in the EQ-5D-5L Health Utility Index score. The Health Utility Index is derived from responses to the five EQ-5D-5L dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) using a country-specific value set. Scores typically range from less than 0 (health states considered worse than death) to 1.0 (full health), with higher scores indicating better health-related quality of life.
Baseline through approximately 36 months.
Patient-Report Outcomes
기간: Baseline through approximately 36 months
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30). Change from baseline in the EORTC QLQ-C30 Global Health Status/Quality of Life Scale score. The Global Health Status/Quality of Life Scale is transformed to a 0 to 100 scale, with higher scores indicating better global health status and quality of life.
Baseline through approximately 36 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Aveta Biomics, Inc.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 7월 1일

기본 완료 (추정된)

2031년 12월 1일

연구 완료 (추정된)

2032년 12월 1일

연구 등록 날짜

최초 제출

2026년 6월 8일

QC 기준을 충족하는 최초 제출

2026년 6월 22일

처음 게시됨 (실제)

2026년 6월 25일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 6월 29일

마지막으로 확인됨

2026년 6월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • AVTA30-01

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

The sponsor does not currently plan to make individual participant data available to researchers outside the study sponsor and its designated representatives. Study results will be made publicly available through ClinicalTrials.gov and scientific publications as appropriate.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

APG-157에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in Kazakhstan

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치

3
구독하다